



ALMA MATER STUDIORUM  
UNIVERSITÀ DI BOLOGNA  
DIPARTIMENTO DI  
SCIENZE MEDICHE E CHIRURGICHE

POLICLINICO DI  
**SANT'ORSOLA**



SERVIZIO SANITARIO REGIONALE  
EMILIA-ROMAGNA  
Azienda Ospedaliero - Universitaria di Bologna

# New Drugs in Hematology

President: Pier Luigi Zinzani

**Bologna,**  
Royal Hotel Carlton  
**May 18-19-20, 2026**

**BOLOGNA**

**BOLOGNA, ROYAL HOTEL CARLTON**

PROGRAM

## REQUESTED AUSPICES

ALMA MATER STUDIORUM - UNIVERSITÀ DEGLI STUDI DI BOLOGNA

REGIONE EMILIA-ROMAGNA

AZIENDA OSPEDALIERO-UNIVERSITARIA  
DI BOLOGNA

AIL ASSOCIAZIONE ITALIANA CONTRO  
LE LEUCEMIE - LINFOMI E MIELOMA  
SEZIONE DI BOLOGNA

SIE - SOCIETÀ ITALIANA DI EMATOLOGIA

## Faculty

<b>Mranjana</b>	<b>Advani</b>	Stanford, Usa	<b>Matthew</b>	<b>Matasar</b>	New Brunswick, Usa
<b>Juan Pablo</b>	<b>Alderuccio</b>	Miami, Usa	<b>Michael</b>	<b>Mauro</b>	New York, Usa
<b>Paul M.</b>	<b>Barr</b>	Rochester, Usa	<b>Jean Marie</b>	<b>Michot</b>	Villejuif, France
<b>Peter</b>	<b>Borchmann</b>	Cologne, Germany	<b>Sattva S.</b>	<b>Neelapu</b>	Houston, Usa
<b>Massimo</b>	<b>Breccia</b>	Roma, Italy	<b>Franck Emmanuel</b>	<b>Nicolini</b>	Lion, France
<b>Elizabeth</b>	<b>Budde</b>	Duarte, Usa	<b>Francesca</b>	<b>Palandri</b>	Bologna, Italy
<b>Carmelo</b>	<b>Carlo-Stella</b>	Rozzano-Mi, Italy	<b>Cristina</b>	<b>Papayannidis</b>	Bologna, Italy
<b>Fausto</b>	<b>Castagnetti</b>	Bologna, Italy	<b>Krish</b>	<b>Patel</b>	Nashville, Usa
<b>Thomas</b>	<b>Cluzeau</b>	Nice, France	<b>Alexander E.</b>	<b>Perl</b>	Philadelphia, Usa
<b>Graham</b>	<b>Collins</b>	London, United Kingdom	<b>Antonio</b>	<b>Pinto</b>	Napoli, Italy
<b>Paolo</b>	<b>Corradini</b>	Milano, Italy	<b>Marc</b>	<b>Raab</b>	Heidelberg, Germany
<b>Antonio</b>	<b>Curti</b>	Bologna, Italy	<b>Alexandros</b>	<b>Rampotas</b>	London, United Kingdom
<b>Alexey V.</b>	<b>Danilov</b>	Duarte, Usa	<b>Delphine</b>	<b>Rea</b>	Paris, France
<b>Naval G.</b>	<b>Daver</b>	Houston, Usa	<b>Paula</b>	<b>Rodriguez Otero</b>	Pamplona, Spain
<b>Matthew S.</b>	<b>Davids</b>	Boston, Usa	<b>Gilles</b>	<b>Salles</b>	New York, Usa
<b>Stephane</b>	<b>De Botton</b>	Villejuif, France	<b>Stephen J.</b>	<b>Schuster</b>	Philadelphia, Usa
<b>Adele</b>	<b>De Masson</b>	Paris, France	<b>John</b>	<b>Seymour</b>	Melbourne, Australia
<b>Johannes</b>	<b>Düll</b>	Würzburg, Germany	<b>Tanya</b>	<b>Siddiqi</b>	Duarte, Usa
<b>Lorenzo</b>	<b>Falchi</b>	New York, Usa	<b>Yuqin</b>	<b>Song</b>	Beijing, China
<b>Sameh R.</b>	<b>Gaballa</b>	Tampa, Usa	<b>Michele</b>	<b>Spina</b>	Aviano-Pn, Italy
<b>Paolo Prospero</b>	<b>Ghia</b>	Milano, Italy	<b>Paolo</b>	<b>Sportoletti</b>	Perugia, Italy
<b>Paola</b>	<b>Guglielmelli</b>	Firenze, Italy	<b>Stephan</b>	<b>Stilgenbauer</b>	Ulm, Germany
<b>Henrik</b>	<b>Hjort-Hansen</b>	Trondheim, Norway	<b>Paolo</b>	<b>Strati</b>	Houston, Usa
<b>Gloria</b>	<b>Iacoboni</b>	Barcelona, Spain	<b>Marion</b>	<b>Subklewe</b>	Munich, Germany
<b>Swaminathan P.</b>	<b>Iyer</b>	Houston, Usa	<b>Anna</b>	<b>Sureda</b>	Barcelona, Spain
<b>Elias J.</b>	<b>Jabbour</b>	Houston, Usa	<b>Alessandra</b>	<b>Tedeschi</b>	Milano, Italy
<b>Wojciech</b>	<b>Jurczak</b>	Krakow, Poland	<b>Steven</b>	<b>Treon</b>	Boston, Usa
<b>Jonathan</b>	<b>Kaufman</b>	Atlanta, Usa	<b>Suzanne</b>	<b>Trudel</b>	Toronto, Canada
<b>Won Seog</b>	<b>Kim</b>	Seoul, Korea	<b>Pankit</b>	<b>Vachhani</b>	Birmingham, Usa
<b>Marina</b>	<b>Kremyanskaya</b>	New York, Usa	<b>Niels</b>	<b>Van De Donk</b>	Amsterdam, The Netherlands
<b>Nicolaus</b>	<b>Kröger</b>	Hamburg, Germany	<b>Frits</b>	<b>Van Rhee</b>	Little Rock, Usa
<b>Shaji</b>	<b>Kumar</b>	Rochester, Usa	<b>Adriano</b>	<b>Venditti</b>	Roma, Italy
<b>Marco</b>	<b>Ladetto</b>	Alessandria, Italy	<b>Michael</b>	<b>Wang</b>	Houston, Usa
<b>Franco</b>	<b>Locatelli</b>	Roma, Italy	<b>Jennifer</b>	<b>Woyach</b>	Columbus, Usa
<b>Maurizio</b>	<b>Martelli</b>	Roma, Italy	<b>Elena</b>	<b>Zamagni</b>	Bologna, Italy
<b>Thomas</b>	<b>Martin</b>	San Francisco, Usa	<b>Pier Luigi</b>	<b>Zinzani</b>	Bologna, Italy



## Monday, May 18, 2026

09.00 a.m. *Welcome and introduction*

### **SESSION I: A 5-Year look at three amazing therapeutic “SUDOKU puzzle”**

*Chairman: P.L. Zinzani*

09.15 a.m. *Diffuse large B-cell lymphoma - G. Salles*

09.40 a.m. *Multiple myeloma - S. Kumar*

10.05 a.m. *Chronic lymphocitic leukemia - S. Stilgenbauer*

### **SESSION II: CAR-T**

*Chairman: S.J. Schuster*

10.30 a.m. *Second generation auto-CAR-T - S.J. Schuster*

10.50 a.m. *Allogeneic CAR-T: do they have a real future? - S.S. Neelapu*

11.10 a.m. *In vivo CAR-T - T. Siddiqi*

### **SESSION III: News in Hodgkin's lymphoma**

*Chairman: A. Sureda*

11.30 a.m. *Actual scenario in frontline advanced stage - P. Borchmann*

11.45 a.m. *With the therapeutic revolution in first line, how will the second line be modified? - A. Sureda*

12.00 p.m. *New agents in R/R patients - R. Advani*

12.15 p.m. *The therapeutic algorithm for elderly and “old old” patients - G. Collins*

12.30 p.m. *CAR-T: can we see the light at the end of the tunnel? - F. Locatelli*

01.00 p.m. *Lunch*

### **LECTURES: update on BTK/BCL6 degraders**

*Chairman: P.L. Zinzani*

02.00 p.m. *ZelevudoMIDE (NX-2127) and bexobrutiDEG (NX-5948) - A.V. Danilov*

02.15 p.m. *BGB-16673 - J. Seymour*

02.30 p.m. *Bifunctional cereblon-dependent ligand-directed degrader of B cell lymphoma 6 - G. Salles*

### **SESSION IV: Acute leukemias**

*Chairmen: A. Curti, A. Venditti*

02.50 p.m. *BCL-2 inhibitors in AML: venetoclax and beyond - T. Cluzeau*

03.05 p.m. *Antibody-drug conjugates in AML: novel targets for novel drugs - A. Curti*

03.20 p.m. *Triplet therapy in AML: a myth or the next frontier - N.G. Daver*

03.35 p.m. *IDH inhibitors in AML - S. De Botton*

04.00 p.m. *Coffee break*

04.30 p.m. *Targeting FLT3: how to choose among inhibitors - A.E. Perl*

04.45 p.m. *Menin-inhibitors in AML and ALL - C. Papayannidis*

05.00 p.m. *Immunotherapies in AML and ALL - M. Subklewe*

05.15 p.m. *BCL-2 inhibition in ALL - E.J. Jabbour*

**SESSION V: Classical Ph1-neg myeloproliferative neoplasms**

Chairmen: *P. Guglielmelli, F. Palandri*

- 08.30 a.m. Interferons and epigenetic modulators: redefining the therapeutic landscape in PV - *F. Palandri*
- 08.45 a.m. Iron metabolism modifiers in PV - *M. Kremyanskaya*
- 09.00 a.m. Evolving strategies for cytopenic myelofibrosis - *P. Guglielmelli*
- 09.15 a.m. Epigenetic modifiers and pro-apoptotic agents in myelofibrosis - *P. Vachhani*
- 09.30 a.m. Monoclonal and bispecific antibodies targeting mutant CALR - *A. Rampotas*
- 09.45 a.m. Best timing and patient selection for allogeneic transplantation in MF - *N. Kröger*
- 10.10 p.m. *Coffee break*

**SESSION VI: Non-Hodgkin's lymphoma (I)**

Chairmen: *C. Carlo-Stella, P. Corradini*

Bispecific antibodies in combinations

- 10.30 a.m. Epcoriab - *L. Falchi*
- 10.45 a.m. Glofitamab - *G. Iacoboni*
- 11.00 a.m. Mosunetuzumab - *E. Budde*
- 11.15 a.m. Odronextamab - *W.S. Kim*

New bispecific and trispecific antibodies

- 11.30 a.m. Surovatamig - *S. Gaballa*
- 11.45 a.m. BAFFR bispecific - *K. Patel*
- 12.00 p.m. Trispecific antibodies - *M. Subklewe*

Monoclonal antibodies and ADC combinations

- 12.15 p.m. Tafasitamab combinations - *J. Duell*
- 12.30 p.m. Loncastuximab combinations - *J.P. Alderuccio*
- 12.45 p.m. Polatuzumab combinations - *M. Matasar*

01.15 p.m. *Lunch*

**SESSION VII: Non-Hodgkin's lymphoma (II)**

Chairmen: *M. Ladetto, M. Martelli*

BTK inhibitors combinations

- 02.15 p.m. Ibrutinib - *K. Patel*
- 02.30 p.m. Zanubrutinib - *P.L. Zinzani*
- 02.45 p.m. Acalabrutinib - *P. Strati*
- 03.00 p.m. Pirtobrutinib - *M. Wang*

BCL-2 inhibitors

- 03.15 pm Sonrotoclax - *M. Wang*

**SESSION VIII: Non-Hodgkin's lymphoma (III)**

Chairmen: *A. Pinto, M. Spina*

- 03.30 p.m. DZD8586, a non-covalent BBB penetrant LYN/BTK inhibitor - *Y. Song*
- 03.45 p.m. Golcadomide - *J.M. Michot*
- 04.00 p.m. Mogamulizumab in combinations - *A. De Masson*
- 04.15 p.m. Zeprumetostat (SHR2554) - *Y. Song*
- 04.30 p.m. DR-01 - *S.P. Iyer*

### **SESSION IX: Chronic myeloid leukemia**

Chairmen: *M. Breccia, F. Castagnetti*

- 04.45 p.m. CML treatment recommendations - *H. Hjorth-Hansen*
- 05.00 p.m. Asciminib - *M. Breccia*
- 05.15 p.m. Ponatinib - *F. Castagnetti*
- 05.30 p.m. Vodobatinib - *F.E. Nicolini*
- 05.45 p.m. Olverembatinib - *D. Rea*
- 06.00 p.m. TERN-701, ELVN-001 and other new agents - *M. Mauro*

## **Wednesday, May 20, 2026**

### **LECTURES**

Chairman: *A. Tedeschi*

- 08.30 a.m. Novel therapies for Waldenström's macroglobulinemia - *S. Treon*
- 08.50 a.m. News from Castleman disease - *F. van Rhee*

### **SESSION X: Chronic lymphocytic leukemia**

Chairmen: *P. Sportoletti, A. Tedeschi*

- 09.15 a.m. First line:
  - Until the progression - *S. Stilgenbauer*
  - Fixed duration - *M.S. Davids*

### **09.45 a.m. Round table: analyzing the guide lines!**

Chairman: *P. Ghia*

Discussants: *P.M. Barr, M.S. Davids, W. Jurczak, S. Stilgenbauer*

- 10.30 a.m. Pirtobrutinib - *P.M. Barr*
- 10.45 a.m. Novel agents - *W. Jurczak*

### **SESSION XI: Multiple myeloma**

Chairmen: *J. Kaufman, E. Zamagni*

- 11.15 a.m. New CARTs in relapsed/refractory patients - *T. Martin*
- 11.30 a.m. Bispecifics against BCMA and GPRC5D in relapsed/refractory patients - *P. Rodriguez Otero*
- 11.45 a.m. Bispecifics in combination and trispecifics in relapsed/refractory patients - *N. van de Donk*
- 12.00 p.m. Moving forward: immunotherapies in newly diagnosed - *M. Raab*
- 12.15 p.m. Celmods alone and in combination in newly diagnosed and relapsed/refractory patients - *J. Kaufman*
- 12.30 p.m. ADC combinations in newly diagnosed and relapsed/refractory patients - *S. Trudel*
- 01.00 p.m. Arrivederci

## GENERAL INFORMATION

### MEETING VENUE

#### Royal Hotel Carlton

Via Montebello, 8 - 40121 Bologna, Italy  
www.royalhotelcarltonbologna.com

### OFFICIAL LANGUAGE

English

### REGISTRATION

Registration is available at [www.ercongressi.it](http://www.ercongressi.it) - section "I nostri congressi/anno 2026"

The registration includes conference kit, participation in the scientific sessions, attendance certificate, coffee break, lunch, slides of the meeting.

### BADGE AND CERTIFICATE OF ATTENDANCE

All registered participants, speakers and sponsors will be given a badge which they must wear to be admitted to the scientific sessions. A certificate will be given to all participants at the end of the meeting.

### ITALIAN CME CREDITS

An Italian CME application has been submitted as follows:

- Provider Studio ER Congressi SRL: ID 828-472999
- **No. 6 CME** credits for Physicians (disciplines: Allergology and Clinical Immunology, Dermatology and Venereology, Hematology, Oncology, Pathological Anatomy, Clinical Biochemistry, Clinical Pathology), Biologists and Chemists
- Educational objective: "linee guida-protocolli-procedure".

### EUROPEAN CME CREDITS

The program of the "New Drugs in Hematology" has been reviewed and approved for CME accreditation by the European Board for Accreditation in Hematology (EBAH), an independent accreditation body endorsed by EHA. The EBAH Unit has approved this educational activity for no. 20 CME credits for Physicians, Biologists and Chemists. To request credits, please fill out the form and return it to the registration desk at the end of the meeting. We remind you that it is necessary to have an EBAH-CME account in order to claim for credits. Attendees can create an EBAH-CME account registering on the website: <http://ebah.org>.

### CHANGES

Parts of the program may be changed without notice.

## ACKNOWLEDGEMENTS

With the unrestricted educational grant of

abbvie

AstraZeneca

BeOne

Bristol Myers Squibb®

Johnson & Johnson

Daiichi-Sankyo

GILEAD

Kite

GSK

KARTOS THERAPEUTICS™

Lilly  
A MEDICINE COMPANY

Roche

Takeda

Incyte

SOLVE  
ON.

MENARINI Stemline

NURIX™

REGENERON  
SCIENCE TO MEDICINE®

sobi

# New Drugs in Hematology

## Scientific Secretariat

Pier Luigi Zinzani  
Istituto di Ematologia  
“Lorenzo e Ariosto Seràgnoli”  
Via Massarenti, 9 - 40138 Bologna, Italy

## Organizing Secretariat

Studio E.R. Congressi  
Via De' Poeti 1/7 - 40124 Bologna, Italy  
Phone +39 051 4210559  
E-mail: [ercongressi@ercongressi.it](mailto:ercongressi@ercongressi.it)  
[www.ercongressi.it](http://www.ercongressi.it)

ER Congressi

